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N-HYDROXYLATED metabolites of several carcinogenic aromatic amines and
amides have now been demonstrated andin many cases, the N-hydroxy compounds
have been shown to have enhanced carcinogenic potency (Miller and Miller, 1966).
Thus N-hydroxy-2-acetamidofluorene produced neoplasms in the guinea-pig, a
species which is normally refractory to the carcinogenic action of 2-acetamido-
fluorene (Miller, Miller and Enomoto, 1964). Similarly, N-hydroxy-2-benzamido-
fluorene is a potent carcinogen in the rat whereas the parent amide, 2-benzamido-
fluorene is virtually inactive (Gutmann, Galitski and Foley, 1966, 1967).
Studies on the metabolism of 4-acetamidostilbene in the rat have established
that an N-hydroxy metabolite is formed, the other hydroxylated metabolites
identified being 4'-hydroxy- and 3-hydroxy-4-acetamidostilbene (Andersen et al.,
1964; Baldwin and Smith, 1965; Baldwin and Romeril, in preparation). In the
present studies, the carcinogenic action of N-hydroxy-4-acetamidostilbene in the
rat has been examined following administration by several routes and its activities
have been compared with those of 4-acetamidostilbene and the 4'-hydroxy
derivative.
EXPERIMENTAL
Compounds
Only the trans isomers of 4-aminostilbene and its derivatives were examined.
These compounds were prepared by the following methods:
4-Acetamidostilbene (AAS) by reduction of 4-nitrostilbene with hydrazine and
Raney Ni and acetylation ofthe resulting amine m.p. 2340 C.
4-Dimethylaminostilbene (DAS) by the action of benzyl magnesium chloride on
p-dimethylaminobenzaldehyde (Sachs and Sachs, 1905) m.p. 148° C.
4'-Hydroxy-4-acetamidostilbene (4'-hydroxy-AAS) by condensation ofp-aceta-
midophenylacetic acidandp-hydroxy-benzaldehyde (Masserani, 1957) m.p. 2380 C.
N-Hydroxy-4-acetamidostilbene (N-hydroxy-AAS) by the partial reduction of
4-nitrostilbene with aluminium amalgam, and acetylation (Baldwin and Smith,
1965) m.p. 200° C.
Animals
Male and female rats of a Wistar strain were used for all tests. These were
obtained either from the inbred colony maintained in the department or from
commercial breeders.BALDWIN, CUNNINGHAM, SMITH AND SURTEES
Oral administration
4-Acetamidostilbene and derivatives were incorporated into a semi-synthetic
5 per cent protein diet (Elson, 1952), at a level of 40 mg./kg. and these diets were
administered so that the average daily dose of compound was 0.5 mg./rat. All
rats were provided with water ad libitum. Groups of 16 male rats, initially 190-
220 g. in weight, receivedthese diets for 224 days (total dose 112 mg./rat). Female
rats, initially 170-180 g. in weight, were treated for 150 days (total dose 75
mg./rat). After carcinogen treatment, rats were maintained on the low protein
diet until tests were terminated.
Subcutaneous injection
Female rats, initially 150-200 g. in weight, received either 3 or 5 subcutaneous
injections at fortnightly intervals of the compounds dissolved in propylene glycol
(total doses 37*5 and 62-5 mg./kg. body weight). Control rats were treated with
propylene glycol.
Intraperitoneal administration to weanling rats
In tests with weanling female rats, initially 6 weeks of age (body weight
50-70 g.), suspensions ofthe compounds, prepared by homogenisation in balanced
salt solution containing gum acacia (1.75 per cent w/v), were injected intra-
peritoneally thrice weekly. Material was prepared freshly for each treatment
and all compounds were injected in a standard volume of 0 4 ml./100 g. body
weight.
RESULTS
Oral administration
There was a pronounced loss of body weight in female rats during the first 4
weeks of feeding N-hydroxy-4-acetamidostilbene in the low protein diet (daily
intake approximately 0.5 mg./rat) and after temporary recoveries, further weight
losses were observed (Fig. 1) so that carcinogen administration was stopped after
22 weeks (total dose 75 mg./rat). At this time, 12 of the initial 16 rats were
surviving, but a further 6 died before the first tumour was observed (30 weeks).
In animals examined early, liver damage was a constant feature. The first evid-
ence ofdamage was a patchy fatty change mainly in the centrilobular region, then
areas of congestion and polymorph infiltration appeared with haemorrhages in the
parenchyma which went on to necrosis, usually well delineated, and eventual cyst
formation. The cellular infiltrate was usually in the periportal areas but the
cystic and haemorrhagic foci appeared irregular in distribution. The cysts often
contained weakly positive PAS staining material. Adenomatous hyperplasia was
sometimes seen in association with the inflammatory response but no liver tumours
were seen and the end picture was of a congested liver showing some areas of
fatty change and large cystic spaces lined with simple flat epithelium.
Of the 6 female rats surviving when tumours were first observed (30 weeks),
5 developed squamous carcinomata associated with the external auditory meatus
and 1 also had an intestinal adenocarcinoma (Table I). This latter tumour
consisted of a mass of irregular acini lined by hyperchromatic columnar cells and
containing mucus and polymorphs. It appeared to be a typical large bowel
carcinoma.
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Male rats tolerated oral administration of N-hydroxy-AAS much better than
females and there was no loss of body weight during the 32 weeks of treatment
(Fig. 1). Tumours were first detected in male rats after 33 weeks and at this time,
there were 13 survivors. When the test was terminated after 50 weeks, 12 rats
(95 per cent) had developed squamous cell carcinomata in the external auditory
meatus. Bilateral ear duct carcinomata were present in 5 rats and 1 also had a
fibrosarcoma associated with the gastro-intestinal tract (Table I).
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FIG. 1.-Changes in body weight following oral administration to rats of 4-acetamidostilbene
(AAS, 0 O) and the N-hydroxy derivative (N-hydroxy-AAS, Fj Li) in a low
protein diet.
4-Acetamidostilbene was well tolerated following oral administration (Fig. 1)
but for comparison with N-hydroxy-AAS treated rats, the compound was fed for
22 weeks (total dose 75 mg./rat) and 32 weeks (total dose 112 mg./rat) in female
and male rats respectively. Ear duct carcinomata were first detected in these
rats between 24 and 26 weeks after the start of treatment at which time all 16
male rats and 13 female rats were surviving. At the completion of the test (48
weeks) ear duct carcinomata had been detected in 11 female and 14 male rats
respectively (Table I). Bilateral ear duct carcinomata were detected in 2 ofthese
rats whilst 1 rat with an ear duct carcinoma at one side also had a spindle cell
sarcoma in the other ear duct region.
4-Dimethylaminostilbene was also well tolerated when fed in a low protein
diet so that the daily intake was approximately 0.5 mg./rat, and the compound
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was fed to both male and female rats for 32 weeks (total dose 112 mg./rat). Ear
duct carcinomata were first detected in these rats after 28 weeks treatment at
which time all 16 males and 11 females were surviving. The incidence of ear duct
carcinomata was much lower in these rats compared to those obtained with
4-acetamidostilbene or the N-hydroxy compound (Table I). Furthermore,
females appeared to be more susceptible than males, final tumour incidence in
males and females being 25 and 55 per cent respectively.
4'-Hydroxy-4-acetamidostilbene (4'-hydroxy-AAS) which was detected as a
major metabolite of AAS and N-hydroxy-AAS (Baldwin and Smith, 1965) was
almost devoid of carcinogenic activity (Table I). Hence, 29 out of the original 32
rats were surviving without any sign of tumour at 50 weeks when tests with the
other compounds were completed. No ear duct tumours were observed in any
rats treated with this compound, the only tumours eventually observed being 2
benign papillomata on the lower jaw, a uterine adenocarcinoma and poorly
differentiated adenocarcinoma probably originating in the adrenals.
Subcutaneous injection
N-Hydroxy-AAS produced a marked chronic inflammatory response following
three subcutaneous injections (1P25 mg./100 g. body weight) at 2-weekly intervals
and 9 of 24 rats were killed within 10 weeks oftreatment with chronic abscesses at
the injection site. The usual picture was of necrosis and haemorrhage with
attempts at the formation of granulation tissue. Individual animals showed
simple pyogenic abscesses, others large necrotic areas with more chronic inflam-
matory changes. In some animals the reparative process was the main feature
with a very cellular reaction containing many mitotic figures and bizarre-looking
cells. Usually the area was well circumscribed and represented an obvious
granulomatous response but in a few animals it was not possible to be certain
whether the picture represented extreme hyperplasia or the development of
malignancy.
Tumours were first detected 40 weeks after the initial injection and at this time
there were 10 survivors. Eight of these rats had developed tumours when the
test was terminated after 60 weeks (Table II). Ear duct carcinomata were
observed in 6 rats whilst 1 had a squamous cell carcinoma at the injection site
and another a mammary adenocarcinoma.
In a second experiment where N-hydroxy-AAS was injected 5 times at weekly
intervals (total dose, 6-25 mg./100 g. body weight), rats survived much better so
that 15 were alive when the first tumour was observed (32 weeks). Six of these
rats developed squamous carcinomata associated with the external auditory
meatus whilst 1 had a spindle cell sarcoma at the injection site (Table II).
4-Acetamidostilbene was much less toxic than the N-hydroxy derivative and
all the rats survived 3 subcutaneous injections at 2-weekly intervals (total dose,
3.75 mg./100 g. body weight). At this dose level, only 1 rat developed a tumour,
a spindle cell sarcoma at the injection site during the period ofthe test (55 weeks).
In the second test when AAS was injected 5 times at weekly intervals (total
dose 6-25 mg./100 g. body weight) tumours were observed in only 2 rats (13 per
cent). Both these tumours were mammary adenocarcinomata and no ear duct
tumours were observed. No tumours were observed in rats treated with propylene
glycol which was used as the vehicle for the aminostilbene compounds (Table II).
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Intraperitoneal administration to weanlingfemale rats
N-Hydroxy-AAS proved to be highly toxic following repeated intraperitoneal
injection into weanling female rats (total dose, 11P2 mg./100 g. body weight) and
whilst rats survived the 4-week period of treatment, all but 2 died during the
following 12 weeks (Table III, Group 1I). Almost every animal showed severe
intra-abdominal effects. These varied from a few scattered adhesions to areas of
necrosis and abscess formation affecting the whole peritoneal cavity and viscera.
Sometimes pleural adhesions were also seen. The capsule of the spleen was
often thickened, perisplenitis was frequently present with macrophage and small
round cell infiltration and occasionally abscesses were seen. Similar changes
were found in the liver and the intestines were often stuck down and attached to
the anterior abdominal wall. In some animals, chronic inflammation with
granulation tissue was present and in the course ofthe healing process, calcification
and lymphoid hyperplasia was seen occasionally.
A similar toxic effect was obtained when the compound was administered at a
lower dose level (total dose 6-0 mg./100 g. body weight) and again only 4 out of
16 rats were surviving when tumours were first observed (59 weeks). Of these
survivors, 3 developed squamous carcinomata associated with the external
auditory meatus but there were no other tumours. In a further experiment
where N-hydroxy-AAS was administered at a still lower dose (total dose 3 0
mg./100 g. body weight) all but 2 rats were surviving when the first tumour was
observed (45 weeks). Ear duct carcinomata were observed in 8 of these rats and
another had a papillary adenocarcinoma invading the diaphragm and mesenteric
fat giving a total tumour incidence of 64 per cent (Table III).
In contrast, rats tolerated 4-acetamidostilbene administered over 8 injections
(total dose 10-0 mg./100 g. body weight) and 13 rats were surviving when the first
tumour was detected after 46 weeks. Ear duct carcinomata were observed in 4
of these rats, 1 also having a mammary adenocarcinoma. In addition 2 rats had
adenocarcinomata ofthe large bowel giving a total tumour incidence of46 per cent
(Table III). In a second test where AAS was administered thrice weekly at a
dosage of 0 7 mg./100 g. body weight (total dose 112 mg./100 g.) all but 1 rat
survived until tumours were first observed (36 weeks). Ear duct carcinomata
developed in 8 of these rats (tumour incidence 53 per cent) but no other tumours
were observed (Table III).
In contrast to the previous report of Andersen et al., (1964) only one of the
weanling rats injected intraperitoneally with 4-acetamidostilbene developed a
mammary adenocarcinoma. In some cases, changes were seen mainly ofa benign
nature with varying degrees of ductal hyperplasia and cystic dilatation. The
duct usually contained stagnating secretion and retention cysts with some
surrounding fibrosis were present in some animals.
Pathogenesis of ear duct tumourformation
The early macroscopic sign of abnormality was the appearance of a fixed
swelling, often lobulated, below and anterior to the ear duct and pinna (Fig. 2).
The mass grew rapidly with distention and eventually ulceration ofthe skin. No
growth was seen to issue from the ear duct itself. A few tumours when fully
developed extended almost from the jaw to the axilla but usually the animal was
killed or ulceration and infection had supervened before this stage was reached.
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Histologically the tumours showed the typical characteristics of squamous
carcinoma the better differentiated showing keratin cysts (Fig. 3). In ear ducts
examined before obvious tumours were present it appeared that changes were
already present in Zymbals gland. This is a small, sebaceous type gland complex
situated anteriorly and medially to the ear duct, deep to the cartilaginous rings
almost at the junction of the osseous and cartilaginous portions of the ear-duct
(Fig. 4). It consists of 3 main lobules and drains into the ear duct through a gap
in the cartilage via a duct (Fig. 5), which may be duplicated, lined by flattened or
cuboidal epithelium. The ear duct epithelium itself contains simple sebaceous
glands.
The first change noticed was dilatation of the lobules with formation of small
cysts (Fig. 6). This occurred in an irregular manner, often commencing in only 1
section ofthe gland but soon involving the ducts throughout their length. Some-
times the lobular dilatation spread to involve all the gland (Fig. 7) but in general 1
or 2 lobules only were affected. The process proceeded to gross dilatation of the
duct and lobules, the lumen of the space being filled with the debris of necrotic
cells and the epithelial lining appeared to undergo squamous metaplasia. Even-
tually the secretory epithelium was replaced by stratified squamous cells with
considerable keratin formation which was desquamated into the lumen.
The mass of squamous epithelium sometimes developed papillary formations
into the centre of the tumour and by further growth formed a circumscribed
keratin cyst with a pseudocapsule of compressed surrounding tissue. At this
stage it could be clearly seen that the ear duct was not involved and that the
tumour was deep to the cartilage and a short distance away from the ear duct
(Fig. 8). Other tumours were less well demarcated with the cystic areas and
tumour cells extending into the neighbouring tissue. The cartilaginous rings were
often found surrounded by tumour and appeared necrotic but there was no direct
invasion ofthe cartilage or bone. Occasionally, the appearances resembled actual
invasion of the ear duct through gaps in the cartilage as shown in Fig. 10. Some
tumours were of a particularly invasive nature and showed extensive infiltration
of muscle (Fig. 9). Secondary deposits in the lymph nodes of the neck were
found in a few animals (Fig. 11).
Zymbals gland lies in close association with the salivary glands and part ofthe
lacrimal gland. No tumour of these glands was found but, changes were seen in
association with neighbouring tumour masses; round cell infiltration and
haemorrhages were notuncommon and sometimes the glands appeared disorganised
with some of the nuclei enlarged and of bizarre shape.
DISCUSSION
Following the discovery by Cramer, Miller and Miller (1960) of N-hydroxy-
2-acetamidofluorene as a urinary metabolite of 2-acetamidofluorene in the rat, it
has been established in several studies that N-hydroxy derivatives of carcinogenic
aromatic amines are also carcinogenic often with increased activity or a reactivity
to a wider range of tissues (see review by Miller and Miller, 1966). The present
studies demonstrating the high carcinogenicity ofN-hydroxy-4-acetamidostilbene
add to the body ofevidence indicating that N-hydroxylation is a critical metabolic
transformation.
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Both N-hydroxy-AAS and the parent amide produced a high incidence of ear
duct carcinomata following oral administration so that it was not possible under
these conditions to assess the relative potencies of the 2 compounds. However,
4'-hydroxy-4-acetamidostilbene which constitutes another major metabolite of
both N-hydroxy-AAS and AAS (Baldwin and Smith, 1965; Baldwin and Romeril,
in preparation) was virtually devoid of activity when administered orally and none
of the rats treated with this compound developed ear duct carcinomata (TableI).
In comparable studies, Andersen et al., (1964) observed a high incidence of ear
duct carcinomata in male rats orally treated with N-hydroxy-AAS or the parent
amide. N-Hydroxy-AAS but not AAS also induced tumours of the gastro-
intestinal tract. These latter findings differ from those obtained in the present
studywhere only 2 rats treated with N-hydroxy-AAS developed intestinal tumours,
and possibly reflect variations in the tissue susceptibilities of the rat strains used
in the two studies.
The enhanced carcinogenicity of N-hydroxy-AAS compared with that of the
parent amide was revealed more convincingly following subcutaneous injection of
the compounds (Table II). Thus tumour incidences of 47 per cent and 80 per cent
were obtained in 2 tests with N-hydroxy-AAS, the majority of the tumours being
ear duct carcinomata. Comparable tests with AAS produced few tumours
(tumour incidences 6 per cent and 13 per cent) and none were ear duct carcinomata.
The greater activity of N-hydroxy-AAS compared with AAS following subcutan-
eous injection of the compounds into rats was also reported by Andersen et al.,
(1964) but in these studies the tumours induced by N-hydroxy-AAS were predom-
inantly mammary carcinomata and no ear duct tumours were detected. The low
susceptibility of mammary tissue in the Wistar rat strain used in the present
studies was further demonstrated by the almost complete lack of response at
these sites to N-hydroxy-AAS or AAS when administered intraperitoneally to
weanling female rats (Table III). The majority of tumours induced by this
treatment were ear duct carcinomata and again the greater activity of the
N-hydroxy-AAS was evident. These results contrast with those ofAndersen et al.,
(1964) who observed a 43 per cent incidence of mammary tumours in immature
female rats treated in a similar manner with N-hydroxy-AAS.
The greatly increased incidence of tumours in treated animals compared with
controls leaves little doubt that the aminostilbene compounds were the carcino-
genic agents in the production of these tumours.
EXPLANATION OF PLATES
FIG. 2.-Gross appearance of established ear duct tumour.
FIG. 3.-Well differentiated tumour of low malignancy, showing many keratin cysts. H.
andE. x37.
FIG. 4.-Zymbals gland. The ear duct epithelium, with simple sebaceous glands, is also
shown separated from the gland by cartilage. H. and E. x 15.
FIG. 5. Zymbals gland, with slight dilatation of one of the lobes, to show the opening into
the ear duct at the junction of the osseous and cartilaginous portions. H. and E. x 15.
FIG. 6.-Part of Zymbals gland showing the sebaceous nature of the cells and early cyst
formation. H. and E. x 90.
FIG. 7.-Cyst formation and dilatation affecting most of the gland. H. and E. x 90.
FIG. 8.-A circumscribed tumour lying some distance from the ear duct, which appears normal.
H. andE. x15.
FIG. 9. Showing infiltration of muscle. H. and E. x 90.
FIG. 10.-Apparent invasion of the ear duct through gaps in the cartilage. H. and E. x 15.
FIG. 11.-Secondary deposits in a lymph node. H. and E. x 90.
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The early changes seen in Zymbals gland, with a progressive development
through squamous metaplasia to proliferation and tumour formation infer that
the gland is the site of origin. A normal Zymbals gland was not seen in the
presence of an ear duct tumour, although occasionally an apparently uninvolved
lobe was present, and supposedly early tumours were clearly separate from the
ear duct, lying deep to the cartilage. When the ear duct epithelium was involved
it appeared to be secondary to invasion or infection.
These observations are in accord with the report of Skoryna, Ross and Rudis
(1951) on the histogenesis of sebaceous gland carcinomata induced in rats by
2-acetamidofluorene. The susceptibility of these sebaceous glands to neoplastic
change is illustrated by their response to a variety of carcinogens including
N-hydroxy-2-acetamidofluorene (Miller, Miller and Hartmann, 1961), benzidine
(Spitz, Maguigan and Dobriner, 1950), urethane, (Tannenbaum et al., 1962),
9,10-dimethyl-1,2-benzanthracene (Geyer et al., 1953; Pollard and Kajima, 1967)
and tris (p-aminophenyl) carbonium pamoate (Schardein and Kaump, 1966).
Earlier reports (Skoryna, Ross and Rudis, 1951) ascribed this susceptibility to the
influence of cystic degeneration of one or more lobules of the sebaceous glands on
the localisation of carcinogen but this was discounted in a later study (Laws,
Rudali, Royer and Mabille, 1955). More recently it has been proposed (Schardein
and Kaump, 1966) thatlobular cystic dilation in theglandduring aging contributes
to tumour development. The direct involvement of carcinogen is supported,
however, by the finding (Baldwin and Romeril, 1965) that radioactive material is
localised in the earductglands inrats treatedwith 14C-labelled 4-acetamidostilbene
or the N-hydroxy-derivative.
The carcinogenic potency of N-hydroxy-AAS when administered by several
routes contrasts with the virtual inactivity of 4'-hydroxy-4-acetamidostilbene
which quantitative metabolism studies with 14C-labelled 4-acetamidostilbene have
shown to be one of the major hydroxylated metabolites (Baldwin and Romeril,
in preparation). The other major hydroxylated metabolite of AAS, 3-hydroxy-
AAS has also been reported to lack carcinogenicity (Andersen et al., 1964) so that
these findings provide considerable evidence in support of the concept that
N-hydroxylation of aromatic amines constitutes a carcinogen activation process.
SUMMARY
N-hydroxy-4-acetamidostilbene (N-hydroxy-AAS) which is a major meta-
bolite of 4-acetamidostilbene (AAS) was shown to be highly carcinogenic following
oral, intraperitoneal or subcutaneous administration to male and female rats.
Irrespective of the route of administration, the majority of the tumours were
squamous cell carcinomata developing from a small sebaceous type gland complex
(Zymbal's gland) situated anteriorly and medially to the external auditory meatus.
Whilst N-hydroxy-AAS and the parent amide (AAS) showed comparable
carcinogenic activities following oral administration, the increased potency of the
N-hydroxy derivative was revealed following subcutaneous and intraperitoneal
administration. In contrast, 4'-hydroxy-AAS which is another major metabolite
ofAAS was virtually devoid of carcinogenic activity. These findings support the
concept that N-hydroxylation of carcinogenic aromatic amines constitutes a
carcinogen activation process.
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